Conference Coverage

No recurrence of cervical cancer seen with simple trachelectomy


 

AT IGCS 2014

References

MELBOURNE – Simple trachelectomy can achieve fertility-sparing outcomes similar to those obtained from radical trachelectomy in women with early-stage cervical cancer without any increased risk of recurrence, according to a poster presented at the biennial meeting of the International Gynecologic Cancer Society.

A retrospective cohort study of 25 patients who underwent a simple vaginal trachelectomy to remove the cervix after a diagnosis of cervical cancer found that 6 of the 10 patients who declared an intention to conceive were successful in doing so.

“The radical trachelectomy procedures [resulted in] a pregnancy rate between 70% and 80%, so we think the simple trachelectomy will do quite well,” said lead author Dr. Shamitha Kathurusinghe, an obstetrics/gynecology trainee at Royal Women’s Hospital, Melbourne.“We had 10 people with the intention to conceive, and we had 10 pregnancies in 6 patients, and our intention to conceive was about 50%,” she said in an interview.

While the majority of patients in the study sought assisted reproductive technologies, some also conceived naturally.

All pregnancies were treated as high risk, and all patients delivered via cesarean section. Two pregnancies were achieved via a surrogate; there was one first-trimester miscarriage; one ectopic pregnancy; and one second-trimester miscarriage, but the cause was unknown.”

Researchers found no incidence of cancer recurrence during the median 54-month follow-up period, among a group of patients which included 7 with stage IA1 disease, 5 with stage IA2, 11 with stage IB1 disease, and 2 with stage IB2 disease.

The study group included 7 cases of squamous cell carcinoma, 10 adenocarcinomas, 4 adenosquamous tumors, 2 adenosarcomas, and 2 neuroendocrine tumors. In all, 48% of patients were nulliparous prior to the procedure.

Dr. Kathurusinghe said surgical treatments for cervical cancer seemed to be shifting away from more radical toward more conservative approaches.

“What we’ve noticed over time is that the gold standard management is a radical hysterectomy, but we’ve gone back from that and said, maybe we can get away without that, let’s do a radical trachelectomy,” Dr. Kathurusinghe said.

“Now we’re slowly going back and saying we can be a little bit less radical and leave a bit more behind.”

While the study included women with stage IB2 tumors, Dr. Kathurusinghe said the general advice would be to use the more conservative procedure up to stage IB1 tumors only.

“Every patient should be considered on an individual basis by a specialist that’s in that area. Sit down with the patient and decide, does this patient need radical therapy? Is this woman still of a childbearing age, [who] would want to preserve their fertility; and can this be an option for that patient?”

Researchers also found that 15 patients actually had no residual disease on the final histopathology, echoing similar findings from an earlier study.

There were no conflicts of interest declared.

obnews@frontlinemedcom.com

Recommended Reading

VIDEO: Public testimony gets heated at FDA panel meeting on morcellation
MDedge Surgery
VIDEO: ‘Improve – but do not abandon – power morcellation’
MDedge Surgery
FDA panel recommends informed consent, labeling changes to address morcellator risk
MDedge Surgery
Study provides cancer risk estimates among women undergoing morcellation
MDedge Surgery
Study provides cancer risk estimates among women undergoing morcellation
MDedge Surgery
Ethicon pulls morcellators off the market, citing ‘uncertain’ risk-benefit
MDedge Surgery
No unexpected leiomyosarcomas in chart review of TVH and LAVH cases
MDedge Surgery
Morcellation shows favorable risk/benefit ratio in decision analysis
MDedge Surgery
Paradigm shift: Prophylactic salpingectomy for ovarian cancer risk reduction
MDedge Surgery
Ovarian cancer often arises from precursor endometriosis
MDedge Surgery